{"id":41060,"date":"2025-09-10T14:51:01","date_gmt":"2025-09-10T06:51:01","guid":{"rendered":"https:\/\/flcube.com\/?p=41060"},"modified":"2025-09-10T14:51:02","modified_gmt":"2025-09-10T06:51:02","slug":"novartis-expands-iptacopan-approval-to-iga-nephropathy-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41060","title":{"rendered":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China"},"content":{"rendered":"\n<p>Swiss pharmaceutical giant <strong>Novartis (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>)<\/strong> announced that its first\u2011in\u2011class oral inhibitor <strong>Iptacopan<\/strong> (Fabhalta) has received <strong>additional approval<\/strong> from the <strong>China National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>IgA nephropathy (IgAN)<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-is-iptacopan\">What is Iptacopan?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong> \u2013 Selectively inhibits complement factor\u202fB, a key driver of the alternative complement pathway.<\/li>\n\n\n\n<li><strong>Current Indications<\/strong> \u2013<\/li>\n\n\n\n<li><strong>Paroxysmal nocturnal hemoglobinuria (PNH)<\/strong> \u2013 Approved April\u202f2024; expanded May\u202f2025 to all adult PNH patients, including those previously treated with complement inhibitors.<\/li>\n\n\n\n<li><strong>C3 glomerulopathy (C3G)<\/strong> \u2013 Approved April\u202f2025; reduces proteinuria in adult patients.<\/li>\n\n\n\n<li><strong>New Indication<\/strong> \u2013 <strong>IgA nephropathy (IgAN)<\/strong> \u2013 First oral complement\u2011inhibitor therapy approved for this common glomerular disease.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-supporting-the-igan-approval\">Clinical Evidence Supporting the IgAN Approval<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Iptacopan<\/th><th>Placebo<\/th><th>% Reduction<\/th><\/tr><\/thead><tbody><tr><td>Morning urine protein\u2011to\u2011creatinine ratio (UPCR) at 2\u202fweeks<\/td><td>Rapid decline<\/td><td>No change<\/td><td>\u2013 (rapid efficacy)<\/td><\/tr><tr><td>Proteinuria at 9\u202fmonths<\/td><td>38.3% \u2193<\/td><td>0% \u2193<\/td><td>38.3\u202f%<\/td><\/tr><tr><td>Safety\/Tolerability<\/td><td>Mild adverse events; no serious safety signals<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The pivotal Phase\u202f3 study demonstrated a <strong>38.3\u202f%<\/strong> reduction in proteinuria after 9\u202fmonths, with a favorable safety profile and rapid onset of action\u2014key factors that enabled the NMPA\u2019s approval.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-broader-development-pipeline\">Broader Development Pipeline<\/h2>\n\n\n\n<p>Novartis is advancing Iptacopan across a spectrum of complement\u2011mediated disorders, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Atypical hemolytic uremic syndrome (aHUS)<\/strong><\/li>\n\n\n\n<li><strong>Immune\u2011complex membranoproliferative glomerulonephritis (IC\u2011MPGN)<\/strong><\/li>\n\n\n\n<li><strong>Lupus nephritis (LN)<\/strong><\/li>\n<\/ul>\n\n\n\n<p>This portfolio underscores Novartis\u2019s commitment to transforming complement\u2011driven diseases worldwide.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-implications\">Market Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First Oral Therapy<\/strong> \u2013 Iptacopan\u2019s oral route offers a convenient alternative to injectable complement inhibitors, potentially improving patient adherence.<\/li>\n\n\n\n<li><strong>China\u2019s Growing Biopharma Market<\/strong> \u2013 The IgAN approval positions Novartis to capture a large patient pool in China, where IgAN prevalence is rising.<\/li>\n\n\n\n<li><strong>Competitive Edge<\/strong> \u2013 By expanding into multiple renal indications, Novartis strengthens its foothold against other complement\u2011targeted agents.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Launch in China<\/strong> \u2013 Commercial rollout slated for Q4\u202f2025.<\/li>\n\n\n\n<li><strong>Real\u2011World Evidence<\/strong> \u2013 Post\u2011marketing studies to confirm long\u2011term efficacy and safety.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 Leverage China data to support regulatory submissions in the EU and US for IgAN and other renal indications.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41061,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[140,865,15],"class_list":["post-41060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novartis","tag-nyse-nvs","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Expands Iptacopan Approval to IgA Nephropathy in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41060\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Expands Iptacopan Approval to IgA Nephropathy in China\" \/>\n<meta property=\"og:description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41060\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-10T06:51:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T06:51:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Expands Iptacopan Approval to IgA Nephropathy in China\",\"datePublished\":\"2025-09-10T06:51:01+00:00\",\"dateModified\":\"2025-09-10T06:51:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060\"},\"wordCount\":325,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1001.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41060#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41060\",\"name\":\"Novartis Expands Iptacopan Approval to IgA Nephropathy in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1001.webp\",\"datePublished\":\"2025-09-10T06:51:01+00:00\",\"dateModified\":\"2025-09-10T06:51:02+00:00\",\"description\":\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41060\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis Expands Iptacopan Approval to IgA Nephropathy in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41060#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Expands Iptacopan Approval to IgA Nephropathy in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China - Insight, China&#039;s Pharmaceutical Industry","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41060","og_locale":"en_US","og_type":"article","og_title":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China","og_description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).","og_url":"https:\/\/flcube.com\/?p=41060","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-10T06:51:01+00:00","article_modified_time":"2025-09-10T06:51:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41060#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41060"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China","datePublished":"2025-09-10T06:51:01+00:00","dateModified":"2025-09-10T06:51:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41060"},"wordCount":325,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41060#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp","keywords":["Novartis","NYSE: NVS","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41060#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41060","url":"https:\/\/flcube.com\/?p=41060","name":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41060#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41060#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp","datePublished":"2025-09-10T06:51:01+00:00","dateModified":"2025-09-10T06:51:02+00:00","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first\u2011in\u2011class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41060#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41060"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41060#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp","width":1080,"height":608,"caption":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41060#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Expands Iptacopan Approval to IgA Nephropathy in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41060"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41060\/revisions"}],"predecessor-version":[{"id":41062,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41060\/revisions\/41062"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41061"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}